Oncology Xagena
The U.S. Food and Drug Administration ( FDA ) has approved an expanded label for Keytruda, an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line ...
Updated preliminary clinical data from an ongoing phase I dose escalation and expansion study evaluating the safety and efficacy of the combination of Monalizumab, a first-in-class monoclonal antibody ...
Radical metastasectomy followed by observation is a commonly used strategy in selected patients with metastatic renal cell carcinoma ( mRCC ). RESORT was the largest prospective study that assesse ...
Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the frontline therapy in advanced penile squamous cell carcinoma ( PSCC ), ...
Nivolumab ( Opdivo ) has shown efficacy and acceptable safety in 2 open-label, multicenter studies ( CheckMate 032 and 275 ) and is approved for patients with metastatic urothelial carcinoma ( mUC ) ...
The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC ) were announced . The results show that the use of Enzalutamide ( Xtand ...
The main aim of adjuvant therapy, which is given after an apparently successful primary cancer treatment, is to reduce the risk of local and distant metastatic disease relapse owing to residual breast ...
Researchers at Columbia University Medical Center ( CUMC ) have discovered that the fusion of two adjacent genes can cause cancer by kicking mitochondria into overdrive and increasing the amount of f ...
Updated data from the advanced non-small cell lung cancer ( NSCLC ) patient cohort of the ongoing phase 1/2 ECHO-202 trial, evaluating Epacadostat, a selective IDO1 enzyme inhibitor, in combination wi ...
Obesity increases the risk of complications during pediatric procedural sedation. The risk of being underweight has not been evaluated in this arena. Researchers therefore investigated the associa ...
BRAF inhibitor and dual BRAF/MEK inhibitors have been approved for the treatment of BRAF-mutated melanoma. Cutaneous squamous cell carcinoma ( cuSCC ) is an adverse event associated with these drugs ...
Cutaneous squamous cell carcinoma ( CSCC ) develops on the head in 80% of cases. Parotid metastasis is rare, but treatment, which associates surgery and radiation therapy, is heavy and prognosis poor. ...
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) injection for intravenous use for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or me ...
Platinum-based chemotherapy for patients with progressing ovarian cancer is more effective with a longer time interval from previous Platinum treatment ( Platinum-free interval ). In 1999, it was hy ...
Results from the phase 3 CheckMate -214 trial evaluating Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) versus Sunitinib ( Sutent ) in patients with previously untreated advanced or metastatic renal ...
